Copyright
©The Author(s) 2022.
World J Cardiol. May 26, 2022; 14(5): 319-328
Published online May 26, 2022. doi: 10.4330/wjc.v14.i5.319
Published online May 26, 2022. doi: 10.4330/wjc.v14.i5.319
Table 2 Baseline characteristics of patients from studies included in the meta-analysis
| Nair et al[10] | Arumugham et al[11] | Prasad et al[12] | van Nunen et al[13] | Edward et al[14] | |
| Number | 25 | 20 | 57 (60 lesions) | 100 | 46 |
| Age [yrs ± SD or yrs (CIs)] | 63 ± 11 | 63.9 ± 9 | 57 ± 8 | 66 ± 8 | 63 ± 10 |
| Women, n (%) | 12 (48) | 4 (20) | 10 (18) | 25 (25) | 9 (20) |
| Body mass index (mean ± SD) | 30.0 ± 5.7 | NA | 27.7 ± 4.1 | 26.7; H kg | 33 ± 7 |
| Hypertension, n (%) | 21 (84) | NA | 51 (90) | 54 | 44 (96) |
| Diabetes mellitus, n (%) | 6 (24) | NA | 26 (46) | 21 | 26 (57) |
| Hyperlipidemia, n (%) | 21 (84) | NA | 39 (68) | 36 | 44 (96) |
| Tobacco use, n (%) | 8 (32) | NA | 24 (42) | 20 | 7 (15) |
| CKD, n (%) | NA | NA | NA | NA | 9 (20) |
| Prior MI, n (%) | 5 (20) | NA | 23 (40) | 36 | NA |
| Prior PCI, n (%) | 8 (32) | NA | NA | 43 | NA |
- Citation: Gill GS, Gadre A, Kanmanthareddy A. Comparative efficacy and safety of adenosine and regadenoson for assessment of fractional flow reserve: A systematic review and meta-analysis. World J Cardiol 2022; 14(5): 319-328
- URL: https://www.wjgnet.com/1949-8462/full/v14/i5/319.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i5.319